Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Correll, Christoph U.
2007.
Balancing Efficacy and Safety in Treatment with Antipsychotics.
CNS Spectrums,
Vol. 12,
Issue. S17,
p.
12.
Keith, Samuel
2009.
Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost–effectiveness.
Expert Review of Neurotherapeutics,
Vol. 9,
Issue. 1,
p.
9.
Karagianis, J.
Grossman, L.
Landry, J.
Reed, V.A.
de Haan, L.
Maguire, G.A.
Hoffmann, V.P.
and
Milev, R.
2009.
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study.
Schizophrenia Research,
Vol. 113,
Issue. 1,
p.
41.
Novick, Diego
Haro, Josep Maria
Suarez, David
Vieta, Eduard
and
Naber, Dieter
2009.
Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.
Schizophrenia Research,
Vol. 108,
Issue. 1-3,
p.
223.
Lencz, Todd
and
Malhotra, Anil K.
2009.
Pharmacogenetics of antipsychotic-induced side effects.
Dialogues in Clinical Neuroscience,
Vol. 11,
Issue. 4,
p.
405.
Kasper, Siegfried
Akimova, Elena
Fink, Martin
and
Lanzenberger, Rupert
2009.
Schizophrenia.
p.
174.
Acosta, Francisco J.
Bosch, Esperanza
Sarmiento, Gerardo
Juanes, Nuria
Caballero-Hidalgo, Araceli
and
Mayans, Teresa
2009.
Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables.
Schizophrenia Research,
Vol. 107,
Issue. 2-3,
p.
213.
Gutiérrez-Casares, José Ramón
Cañas, Fernando
Alonso-Escolano, David
Hidalgo-Borrajo, Rebeca
and
Rodríguez-Morales, Alexander
2010.
Adherence to Treatment and Therapeutic Strategies in Schizophrenic Patients: The ADHERE Study.
CNS Spectrums,
Vol. 15,
Issue. 5,
p.
327.
Cooper, GD
Goudie, AJ
and
Halford, JCG
2010.
Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats.
Journal of Psychopharmacology,
Vol. 24,
Issue. 7,
p.
1069.
Verma, Swapna
Subramaniam, Mythily
Abdin, Edimansyah
Sim, Kang
Su, Alex
Lee, Nelson
and
Chong, Siow Ann
2010.
Safety and efficacy of long‐acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6‐month open‐label trial in Asian patients.
Human Psychopharmacology: Clinical and Experimental,
Vol. 25,
Issue. 3,
p.
230.
Agid, Ofer
Foussias, George
and
Remington, Gary
2010.
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
Expert Opinion on Pharmacotherapy,
Vol. 11,
Issue. 14,
p.
2301.
Gaebel, Wolfgang
Schreiner, Andreas
Bergmans, Paul
de Arce, Rosario
Rouillon, Frédéric
Cordes, Joachim
Eriksson, Lars
and
Smeraldi, Enrico
2010.
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial.
Neuropsychopharmacology,
Vol. 35,
Issue. 12,
p.
2367.
Lepage, Martin
Bodnar, Michael
Joober, Ridha
and
Malla, Ashok
2010.
Is there an association between neurocognitive performance and medication adherence in first episode psychosis?.
Early Intervention in Psychiatry,
Vol. 4,
Issue. 2,
p.
189.
Olivares, José M
Pinal, Beatriz
and
Cinos, Carmen
2011.
Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia.
Neuropsychiatry,
Vol. 1,
Issue. 3,
p.
275.
Beck, Eva-Marina
Cavelti, Marialuisa
Wirtz, Markus
Kossowsky, Joe
and
Vauth, Roland
2011.
How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.
Psychiatry Research,
Vol. 187,
Issue. 1-2,
p.
55.
Gopal, S
Vijapurkar, U
Lim, P
Morozova, M
Eerdekens, M
and
Hough, D
2011.
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
Journal of Psychopharmacology,
Vol. 25,
Issue. 5,
p.
685.
Macfadden, Wayne
DeSouza, Cherilyn
Crivera, Concetta
Kozma, Chris M
Dirani, Riad D
Mao, Lian
and
Rodriguez, Stephen C
2011.
Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results.
BMC Psychiatry,
Vol. 11,
Issue. 1,
Daltio, Claudiane Salles
Mari, Jair Jesus
and
Ferraz, Marcos Bosi
2011.
Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo.
Revista de Saúde Pública,
Vol. 45,
Issue. 1,
p.
14.
Newton, Richard
Hustig, Harry
Lakshmana, Raju
Lee, Joseph
Motamarri, Balaji
Norrie, Peter
Parker, Robert
and
Schreiner, Andreas
2012.
Practical guidelines on the use of paliperidone palmitate in schizophrenia.
Current Medical Research and Opinion,
Vol. 28,
Issue. 4,
p.
559.
de Arce Cordón, Rosario
Eding, Evelin
Marques-Teixeira, Joao
Milanova, Vihra
Rancans, Elmars
and
Schreiner, Andreas
2012.
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
European Archives of Psychiatry and Clinical Neuroscience,
Vol. 262,
Issue. 2,
p.
139.